Lycera isa preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. Lyceraâ€™s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.
Funding Rounds (3) - $45MUpdate
Board Members and Advisors (4)Update
InterWest invests an average of about $7 - 15 million over the span of their involvement with...
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs,...
EDF has cultivated a deep and productive network. They have put their network to work for present...
Clarus Ventures is a life sciences venture capital firm.
2800 Plymouth Rd.
NCRC, Building 26
Ann Arbor, MI 48109